Dhyan Chandra, Ph.D., Associate Professor of Oncology, Department of Pharmacology & Therapeutics at Roswell Park Cancer Center. In this video, he discusses the article – Received a two-year, $240,000 grant from the American Cancer Society to study cytochrome c deficiency in African American men.
BUFFALO, New York " In the United States, African American males have the highest prevalence of prostate cancer and the worst prognosis. Two Roswell Park Comprehensive Cancer Center teams will use new money from the US Department of Defense and the American Cancer Society to study and eliminate prostate cancer health disparities.
African American men are also more likely than men from other racial and ethnic groups to be diagnosed with a very aggressive form of prostate cancer at a younger age. The role of other contributing factors, such as genetic and epigenetic differences in susceptibility and treatment response, is largely unknown. Race-related differences in access to prostate cancer screening and treatment play a large role in these persistent health disparities, but the role of other contributing factors, such as genetic and epigenetic differences in susceptibility and treatment response, is largely unknown.
The US Department of Defense awarded Anna Woloszynska, Ph.D., Associate Professor of Oncology in the Department of Pharmacology and Therapeutics at Roswell Park, a two-year, $613,000 grant to explore the genetic and epigenetic vulnerabilities of prostate cancer in African American men.
The American Cancer Society awarded Dhyan Chandra, Ph.D., Professor of Oncology in the Department of Pharmacology and Therapeutics, a two-year, $240,000 grant to research cytochrome c deficiency in African American men.